Copertina

Treatment acceptability for disease‐modifying therapy for type 1 diabetes ( T1D )—Views from parents of children with presymptomatic T1D

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Lauren M. Quinn, Olga Boiko, Josephine Elliott, Matthew Randell, Ian Litchfield, Felicity Boardman, Renuka P. Dias, Sheila M. Greenfield, Parth Narendran
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Diabetes, Obesity and Metabolism
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Advancing Early‐Stage Type 1 Diabetes Care: Future Focused Pathways for Identification, Screening, Diagnosis, and Monitoring
di: Chantal Mathieu, et al.
Pubblicazione: (2026)

Treatment effect of semaglutide 2.4 mg on health‐related quality of life from STEP 1 SF‐6D derived from SF ‐36 with Australian weights
di: Pavol Kral, et al.
Pubblicazione: (2024)

Efficacy and safety of once‐weekly insulin icodec in type 2 diabetes: A meta‐analysis of ONWARDS phase 3 randomized controlled trials
di: Sahana Shetty, et al.
Pubblicazione: (2024)

Sex as a modifier of genetic risk for type 1 diabetes
di: Hui‐Qi Qu, et al.
Pubblicazione: (2025)

Interactive online calculator for estimation of muscle and hepatic insulin sensitivity in adults with Type 1 diabetes using clinical and research biomarkers
di: Andrzej S. Januszewski, et al.
Pubblicazione: (2026)

Clinical characteristics and outcomes of diabetes‐related ketoacidosis ( DKA ) in sodium‐glucose co‐transporter‐2 inhibitor ( SGLT2i ) users with type 2 diabetes
di: Angelica Sharma, et al.
Pubblicazione: (2025)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
di: Irl B. Hirsch, et al.
Pubblicazione: (2024)

Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model
di: Marga A. G. Helmink, et al.
Pubblicazione: (2024)

A Four‐Variant T1D Genetic Risk Score to Classify Type 1 and Monogenic Diabetes in Chinese Patients
di: Wei Liu, et al.
Pubblicazione: (2026)

Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
di: Noga C. Minsky, et al.
Pubblicazione: (2025)

Cost‐Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries
di: Johan Jendle, et al.
Pubblicazione: (2026)

Sleep duration and association with cardiometabolic health in adolescents and adults with type 1 diabetes: Results from the BCQR‐T1D study
di: Stacey L. Simon, et al.
Pubblicazione: (2024)

Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study
di: Christina Baechle, et al.
Pubblicazione: (2024)

Pre‐dinner walks may be superior to post‐dinner walks for glucose time in range in adults with type 1 diabetes on hybrid closed‐loop insulin delivery systems
di: Lauren V. Turner, et al.
Pubblicazione: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
di: Ruoyang Jiao, et al.
Pubblicazione: (2024)

An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes
di: Geremia B. Bolli, et al.
Pubblicazione: (2025)

Safety and efficacy of hybrid closed‐loop insulin pump therapy in adolescents and adults with type 1 diabetes in China
di: Jing Shen, et al.
Pubblicazione: (2025)

Role of the liver in the sustained normalisation of A1c over 2 years following short‐term insulin therapy in early type 2 diabetes
di: Andrew Wu, et al.
Pubblicazione: (2024)

One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA
di: Mengqing Zhang, et al.
Pubblicazione: (2024)

Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
di: Juliana de Oliveira Costa, et al.
Pubblicazione: (2024)

Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist
di: Luděk Horváth, et al.
Pubblicazione: (2025)

No evidence from euglycaemic–hyperinsulinaemic clamp studies for greater insulin sensitivity in adults with type 1 diabetes using insulin pump versus multiple daily insulin injections—Post hoc meta‐analysis
di: Andrzej S. Januszewski, et al.
Pubblicazione: (2025)

Incretin‐based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta‐analysis of randomized controlled trials
di: Thomaz Alexandre Costa, et al.
Pubblicazione: (2025)

Social disadvantage and technology use among adults with type 1 diabetes in Quebec: A cross‐sectional study using data from the Canadian T1D ( BETTER ) Registry
di: Parisa Khodabandehloo, et al.
Pubblicazione: (2025)

Human adipose tissue expression of uncoupling protein 1 in response to intravenous administration of B‐type natriuretic peptide hormone: Results from a randomized controlled crossover study
di: Katherine N. Bachmann, et al.
Pubblicazione: (2024)

GLP ‐1–based therapies, the stepwise trap, and missed surgical windows: A policy perspective on delayed access to bariatric surgery
di: Kuo‐Feng Hsu
Pubblicazione: (2025)

Efficacy and safety of once‐weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta‐analysis
di: Ludovico Di Gioia, et al.
Pubblicazione: (2025)

The interaction of vitamin D supplementation with Omentin‐1 gene polymorphism on metabolic biomarkers, omentin‐1 levels and anthropometric measures in women with prediabetes: A double‐blind randomized controlled trial
di: Roghayeh Molani‐Gol, et al.
Pubblicazione: (2025)

Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies
di: Reimar W. Thomsen, et al.
Pubblicazione: (2025)

Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
di: Paschalis Karakasis, et al.
Pubblicazione: (2024)

If treating obesity with GLP ‐1‐based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials
di: Anastasios Tentolouris, et al.
Pubblicazione: (2026)

Real‐world evaluation of automated insulin delivery therapy in type 1 diabetes: A multicentre study across regional and metropolitan Queensland, Australia
di: Akash Konantambigi, et al.
Pubblicazione: (2025)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
di: Filip K. Knop, et al.
Pubblicazione: (2024)

The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real‐world retrospective cohort study
di: Sophie Haughton, et al.
Pubblicazione: (2025)

Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post‐hoc analysis from a double‐blinded randomized controlled trial
di: Melissa‐Rosina Pasqua, et al.
Pubblicazione: (2025)

Evaluating biased agonism of glucagon‐like peptide‐1 ( GLP ‐1) receptors to improve cellular bioenergetics: A systematic review
di: Sabrina Wong, et al.
Pubblicazione: (2025)

Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel‐group clinical trial sub‐study
di: Jean‐Pierre Riveline, et al.
Pubblicazione: (2026)

Low levels of soluble neuropilin‐1 were associated with depression in adults with newly diagnosed type 2 diabetes
di: E. O. Melin, et al.
Pubblicazione: (2025)

Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis
di: Deep Dutta, et al.
Pubblicazione: (2025)

GLP ‐1 receptor agonist therapy for relapsed diabetes following 6q24‐related transient neonatal diabetes due to paternal uniparental disomy: A case report
di: Francesco Giangreco, et al.
Pubblicazione: (2025)